MacroGenics stock falls 3.95 percent as pipeline expands
Published on 09/24/2026 at 16:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
MacroGenics stock fell 3.95 percent to USD 3.65 on Nasdaq on September 24, 2026, leaving the shares 28.1 percent below their 52-week high of USD 5.08. The move came as investors weighed a leaner operating model against a still loss-making clinical pipeline.
Revenue misses the consensus
For Q2 2026, MacroGenics reported revenue of USD 32.83 million versus a consensus estimate of USD 59.14 million, a shortfall of USD 26.31 million, according to MarketBeat. The same report said quarterly EPS was USD 0.31, beating the consensus estimate of a USD 0.08 loss by USD 0.39.
The contrast matters because partnership income can make MacroGenics revenue highly uneven. A revenue miss alongside an EPS beat places greater weight on cash resources and clinical execution than on a single quarter's sales line.
Cash supports the pipeline
At the H.C. Wainwright conference on September 16, 2026, MacroGenics described pro forma cash of USD 327 million and a cash runway through the end of 2028, according to Investing.com. The company also reported more than USD 300 million in partnership revenue over the prior year.
The presentation highlighted eight development assets, including four clinical-stage antibody-drug conjugates and three active Gilead T-cell engager programs. MacroGenics also said the sale of its manufacturing operation to Bora Pharmaceuticals brought in USD 120 million, supporting the shift to an outsourced model.
Stock remains below yearly high
MacroGenics stock was trading at USD 3.65 on Nasdaq at 10:38 a.m. ET on September 24, 2026. Its intraday range was USD 3.62 to USD 3.87, while the market capitalization was USD 232,005,315.
MacroGenics market snapshot
- Company: MacroGenics, Inc.
- Ticker: MGNX
- Trading venue: Nasdaq Global Select Market
- Price: USD 3.65, September 24, 2026, 10:38 a.m. ET
- Market capitalization: USD 232,005,315 as of September 24, 2026
- 52-week range: USD 1.29-5.08 as of September 24, 2026
- Sector / Industry: Healthcare / Biotechnology
